碳水化合物反应元件结合蛋白
医学
转录组
糖尿病肾病
肾
肾脏疾病
内科学
内分泌学
糖尿病
疾病
转录活性
基因
生物信息学
下调和上调
癌症研究
药理学
生物信息学
肾素-血管紧张素系统
糖基化终产物
受体
基因表达
作者
Thanh Phuong Nguyen,Susumu Suzuki,Koji Okamoto,Ryo Ito,Hiroto Mizuno,Sora Fujita,Takumi Kouketsu,Kotone Teshima,Shun Sawatsubashi,Tatsuya Takemoto,Hiroyuki Yamakoshi,Masaya Takahashi,Mayu Kuroda,Yusuke Sasano,Yuta Yoshizaki,Yotaro Matsumoto,Kosuke Ohsawa,Genki Kudo,Takatsugu Hirokawa,Shigeaki Kato
标识
DOI:10.1073/pnas.2537870123
摘要
Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element–binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potential causal driver. A chemical screen based on ChREBP transcriptional activity identified D-532 as a small-molecule inhibitor that is effective in human and rodent cells. Oral administration of D-532 protected multiple diabetic mouse models from DKD progression and suppressed ChREBP and its downstream targets, including genes associated with excessive reactive oxygen species production. These findings position ChREBP as a pharmacologically targetable transcriptional driver of DKD and provide proof of concept that ChREBP inhibition can confer renal protection.
科研通智能强力驱动
Strongly Powered by AbleSci AI